Top

Current Dermatology Reports

Published in:

18-11-2023 | Atopic Dermatitis | REVIEW

JAK Inhibitor Use for the Inpatient Dermatologist

Authors: Eric Xia, Ahana Gaurav, Allison Yan, Arash Mostaghimi

Published in: Current Dermatology Reports | Issue 4/2023

Abstract

Purpose of Review

JAK inhibitors (JAKis) are a novel class of therapeutics that have shown great promise in dermatology. This review provides an overview of the role of JAKis in inpatient dermatology and highlights their potential for future applications.

Recent Findings

The impact of JAKis on a range of inflammatory signals, in combination with a potential for rapid onset of efficacy, suggests that they may have a role in the treatment of diseases seen in the inpatient setting. Several JAKis are now FDA-approved to treat conditions including atopic dermatitis, psoriasis, and graft-versus-host disease. Emerging data suggests that these inhibitors may have therapeutic benefit in DRESS syndrome, hidradenitis suppurativa, and dermatomyositis.

Summary

JAKis have demonstrated efficacy in a wide variety of dermatologic conditions that can be acutely managed in the inpatient setting. Many of these conditions are in need for new therapeutics, especially for nonresponsive or refractory disease. There is likely to be a proliferation of JAKis used for a wider variety of dermatologic conditions in the future.

• Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736–44. https://doi.org/10.1016/j.jaad.2016.12.005. Provides a broad overview of the use of JAK inhibitors in various dermatologic conditions.

• Chapman S, Kwa M, Gold LS, Lim HW. Janus kinase inhibitors in dermatology: part I. A comprehensive review. J Am Acad Dermatol. 2022;86(2):406–13. https://doi.org/10.1016/j.jaad.2021.07.002. Part 1 of a two-part review of JAK inhibitors in dermatology focusing on atopic dermatitis and psoriasis. Part 1 also covers select smaller studies addressing other dermatologic conditions such as hidradenitis suppurativa and graft vs host disease.

Hu X, Li J, Fu M, Zhao X, Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402. https://doi.org/10.1038/s41392-021-00791-1.CrossRefPubMedPubMedCentral

Shawky AM, Almalki FA, Abdalla AN, Abdelazeem AH, Gouda AM. A comprehensive overview of globally approved JAK inhibitors. Pharmaceutics. 2022;14(5). https://doi.org/10.3390/pharmaceutics14051001.

Samuel C, Cornman H, Kambala A, Kwatra SG. A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. Dermatol Ther (Heidelb). 2023;13(3):729–49. https://doi.org/10.1007/s13555-023-00892-5.CrossRefPubMed

Aihie O, Dyer JA. JAK Inhibitors: a new weapon in the skin care providers’ arsenal. Mo Med. 2023;120(1):45–8.PubMedPubMedCentral

• Chapman S, Gold LS, Lim HW. Janus kinase inhibitors in dermatology: part II. A comprehensive review. J Am Acad Dermatol. 2022;86(2):414–22. https://doi.org/10.1016/j.jaad.2021.06.873. Part 2 of a two-part review of JAK inhibitors in dermatology focusing on conditions such as alopecia areata, vitiligo, sarcoidosis, and systemic lupus erythematosus.

King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. Lancet. 2023;401(10387):1518–29. https://doi.org/10.1016/S0140-6736(23)00222-2.CrossRefPubMed

Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143(1):1–11. https://doi.org/10.1016/j.jaci.2018.10.032.CrossRefPubMed

10.

Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol. 2021;148(4):927–40. https://doi.org/10.1016/j.jaci.2021.08.009.CrossRefPubMedPubMedCentral

11.

Eichner A, Wohlrab J. Pharmacology of inhibitors of Janus kinases - part 1: pharmacokinetics. J Dtsch Dermatol Ges. 2022;20(11):1485–99. https://doi.org/10.1111/ddg.14921.CrossRefPubMed

12.

Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol. 2019;10:2847. https://doi.org/10.3389/fimmu.2019.02847.CrossRefPubMedPubMedCentral

13.

•• Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255–66. https://doi.org/10.1016/S0140-6736(20)30732-7. Results from a randomised phase 3 trial supporting the safety profile and efficacy of abrocitinib in patients ages 12 and over with moderate-to-severe atopic dermatitis.

14.

•• Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151–68. https://doi.org/10.1016/S0140-6736(21)00588-2. Results from two different phase 3 trials suggesting upadacitinib monotherapy may be a safe, effective option in teenagers and adults with atopic dermatitis.

15.

King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two Phase 3 Trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687–99. https://doi.org/10.1056/NEJMoa2110343.CrossRefPubMed

16.

• Chang PH, Huang SF, Chang PS, Yu Y. Safety considerations of systemic Janus kinase inhibitors in atopic dermatitis applications. J Dermatol. 2021;48(11):1631–9. https://doi.org/10.1111/1346-8138.16116. Reviews the evidence of the safety and adverse effects of JAK inhibitors used in the treatment of atopic dermatitis.

17.

•• Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Leung DYM, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021;85(4):863–72. https://doi.org/10.1016/j.jaad.2021.04.085. Results from 2 phase 3 trials supporting the safety and efficacy of the topical JAK inhibitor ruxolitinib cream in treating atopic dermatitis.

18.

•• Armstrong AW, Gooderham M, Warren RB, Papp KA, Strober B, Thaci D, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29–39. https://doi.org/10.1016/j.jaad.2022.07.002. Results from a phase 3 trial supporting the efficacy and safety profile of deucravacitinib compared with placebo and apremilast in plaque psoriasis.

19.

Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, et al. Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371–9. https://doi.org/10.1001/jamadermatol.2019.2855.CrossRefPubMedPubMedCentral

20.

Bissonnette R, Maari C, Forman S, Bhatia N, Lee M, Fowler J, et al. The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study. Br J Dermatol. 2019;181(4):733–42. https://doi.org/10.1111/bjd.17932.CrossRefPubMedPubMedCentral

21.

Xie F, Yun H, Bernatsky S, Curtis JR. Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments. Arthritis Rheumatol. 2016;68(11):2612–7. https://doi.org/10.1002/art.39761.CrossRefPubMedPubMedCentral

22.

• Hoisnard L, Lebrun-Vignes B, Maury S, Mahevas M, El Karoui K, Roy L, et al. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Sci Rep. 2022;12(1):7140. https://doi.org/10.1038/s41598-022-10777-w. Restrospective study of the WHO pharmacovigilance database assessing safety data and adverse effects of the first three approved JAK inhibitors: ruxolitinib, tofacitinib and baricitinib.

23.

Greif CS, Srivastava D, Nijhawan RI. Janus kinase inhibitors and non-melanoma skin cancer. Curr Treat Options Oncol. 2021;22(2):11. https://doi.org/10.1007/s11864-020-00815-y.CrossRefPubMed

24.

Scott FI, Mamtani R, Brensinger CM, Haynes K, Chiesa-Fuxench ZC, Zhang J, et al. Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer. JAMA Dermatol. 2016;152(2):164–72. https://doi.org/10.1001/jamadermatol.2015.3029.CrossRefPubMedPubMedCentral

25.

Wollenhaupt J, Silverfield J, Lee EB, Curtis JR, Wood SP, Soma K, et al. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol. 2014;41(5):837–52. https://doi.org/10.3899/jrheum.130683.CrossRefPubMed

26.

Papp KA, Krueger JG, Feldman SR, Langley RG, Thaci D, Torii H, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol. 2016;74(5):841–50. https://doi.org/10.1016/j.jaad.2016.01.013.CrossRefPubMed

27.

Jordan Bruno X, Koh I, Lutsey PL, Walker RF, Roetker NS, Wilkinson K, et al. Venous thrombosis risk during and after medical and surgical hospitalizations: the medical inpatient thrombosis and hemostasis (MITH) study. J Thromb Haemost. 2022;20(7):1645–52. https://doi.org/10.1111/jth.15729.CrossRefPubMedPubMedCentral

28.

Clowse ME, Feldman SR, Isaacs JD, Kimball AB, Strand V, Warren RB, et al. Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis. Drug Saf. 2016;39(8):755–62. https://doi.org/10.1007/s40264-016-0431-z.CrossRefPubMedPubMedCentral

29.

Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford). 2019;58(Suppl 1):i34–42. https://doi.org/10.1093/rheumatology/key287.CrossRefPubMed

30.

Wieringa JW, van der Woude CJ. Effect of biologicals and JAK inhibitors during pregnancy on health-related outcomes in children of women with inflammatory bowel disease. Best Pract Res Clin Gastroenterol. 2020;44–45:101665. https://doi.org/10.1016/j.bpg.2019.101665.CrossRefPubMed

31.

• Nash P, Kerschbaumer A, Dorner T, Dougados M, Fleischmann RM, Geissler K, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis. 2021;80(1):71–87. https://doi.org/10.1136/annrheumdis-2020-218398. A consensus study that assesses the efficacy and safety of JAK inhibitors and provides points to consider/management guidelines.

32.

Na CH, Chung J, Simpson EL. Quality of life and disease impact of atopic dermatitis and psoriasis on children and their families. Children (Basel). 2019;6(12). https://doi.org/10.3390/children6120133.

33.

Gochnauer H, Valdes-Rodriguez R, Cardwell L, Anolik RB. The psychosocial impact of atopic dermatitis. Adv Exp Med Biol. 2017;1027:57–69. https://doi.org/10.1007/978-3-319-64804-0_6.CrossRefPubMed

34.

Haque A, Ahmed F, Amanullah A. Atopic dermatitis therapeutic algorithm of JAK-inhibitors and IL-4/IL-13 antagonists utilizing patient profiles and drug efficacy. J Clin Aesthet Dermatol. 2023;16(2):11–3.PubMedPubMedCentral

35.

Kwa L, Silverberg JI. Emergency department visits for atopic dermatitis are common and costly in the United States. Journal of the American Academy of Dermatology. 2018;79(3):Ab128–Ab.

36.

Edigin E, Kichloo A, El-Amir Z, Wani F, Eseaton PO, Shaka H. National trends in hospitalizations of atopic dermatitis adult patients: a 21-year longitudinal United States population-based study. J Am Acad Dermatol. 2022;87(1):153–7. https://doi.org/10.1016/j.jaad.2021.06.882.CrossRefPubMed

37.

Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT. 2013;2(3):e24137. https://doi.org/10.4161/jkst.24137.CrossRefPubMedPubMedCentral

38.

Stander S, Kwatra SG, Silverberg JI, Simpson EL, Thyssen JP, Yosipovitch G, et al. Early itch response with abrocitinib is associated with later efficacy outcomes in patients with moderate-to-severe atopic dermatitis: subgroup analysis of the randomized phase III JADE COMPARE trial. Am J Clin Dermatol. 2023;24(1):97–107. https://doi.org/10.1007/s40257-022-00738-4.CrossRefPubMed

39.

Silverberg JI, Hong HC, Thyssen JP, Calimlim BM, Joshi A, Teixeira HD, et al. Comparative efficacy of targeted systemic therapies for moderate to severe atopic dermatitis without topical corticosteroids: systematic review and network meta-analysis. Dermatol Ther (Heidelb). 2022;12(5):1181–96. https://doi.org/10.1007/s13555-022-00721-1.CrossRefPubMed

40.

Fiuza-Luces C, Simpson RJ, Ramirez M, Lucia A, Berger NA. Physical function and quality of life in patients with chronic GvHD: a summary of preclinical and clinical studies and a call for exercise intervention trials in patients. Bone Marrow Transplant. 2016;51(1):13–26. https://doi.org/10.1038/bmt.2015.195.CrossRefPubMed

41.

Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7(5):340–52. https://doi.org/10.1038/nri2000.CrossRefPubMed

42.

Martini DJ, Chen YB, DeFilipp Z. Recent FDA approvals in the treatment of graft-versus-host disease. Oncologist. 2022;27(8):685–93. https://doi.org/10.1093/oncolo/oyac076.CrossRefPubMedPubMedCentral

43.

Garnett C, Apperley JF, Pavlu J. Treatment and management of graft-versus-host disease: improving response and survival. Ther Adv Hematol. 2013;4(6):366–78. https://doi.org/10.1177/2040620713489842.CrossRefPubMedPubMedCentral

44.

Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020;382(19):1800–10. https://doi.org/10.1056/NEJMoa1917635.CrossRefPubMed

45.

Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, et al. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Engl J Med. 2021;385(3):228–38. https://doi.org/10.1056/NEJMoa2033122.CrossRefPubMed

46.

Sluczanowska-Glabowska S, Ziegler-Krawczyk A, Szumilas K, Pawlik A. Role of Janus kinase inhibitors in therapy of psoriasis. J Clin Med. 2021;10(19). https://doi.org/10.3390/jcm10194307.

47.

Finstad A, Alhusayen R. Healthcare use among psoriasis patients: a population-based study of emergency department and inpatient care J Cutan Med Surg. 2022;26(3):327 328, Artn12034754211067474. https://doi.org/10.1177/12034754211067474.

48.

Edigin E, Rivera Pavon MM, Eseaton PO, Manadan A. National trends of psoriasis hospitalizations: a 2-decade longitudinal United States population based study. J Eur Acad Dermatol Venereol. 2021;35(12):e928–30. https://doi.org/10.1111/jdv.17590.CrossRefPubMed

49.

Polivka L, Oubaya N, Bachelez H, Paul C, Richard MA, Beylot-Barry M, et al. Trends in hospitalization rates for psoriasis flares since the introduction of biologics: a time series in France between 2005 and 2015. J Eur Acad Dermatol Venereol. 2018;32(11):1920–9. https://doi.org/10.1111/jdv.15044.CrossRefPubMed

50.

Dendrou CA, Cortes A, Shipman L, Evans HG, Attfield KE, Jostins L, et al. Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity. Sci Transl Med. 2016;8(363):363ra149. https://doi.org/10.1126/scitranslmed.aag1974.

51.

Krueger JG, McInnes IB, Blauvelt A. Tyrosine kinase 2 and Janus kinase-signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. J Am Acad Dermatol. 2022;86(1):148–57. https://doi.org/10.1016/j.jaad.2021.06.869.CrossRefPubMed

52.

•• Strober B, Thaci D, Sofen H, Kircik L, Gordon KB, Foley P, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023;88(1):40–51. https://doi.org/10.1016/j.jaad.2022.08.061. Results from another 52-week phase 3 trial supporting the efficacy and safety profile of deucravacitinib compared with placebo and apremilast in plaque psoriasis.

53.

von Stebut E, Boehncke WH, Ghoreschi K, Gori T, Kaya Z, Thaci D, et al. IL-17A in Psoriasis and beyond: cardiovascular and metabolic implications. Front Immunol. 2019;10:3096. https://doi.org/10.3389/fimmu.2019.03096.CrossRef

54.

Wei BM, Fox LP, Kaffenberger BH, Korman AM, Micheletti RG, Mostaghimi A, et al. Drug-induced hypersensitivity syndrome / drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, Pathogenesis, Clinicopathological Features, and Prognosis. J Am Acad Dermatol. 2023. https://doi.org/10.1016/j.jaad.2023.02.072.

55.

Damsky WE, Vesely MD, Lee AI, Choi J, Meyer AC, Chen M, et al. Drug-induced hypersensitivity syndrome with myocardial involvement treated with tofacitinib. JAAD Case Rep. 2019;5(12):1018–26. https://doi.org/10.1016/j.jdcr.2019.07.004.CrossRefPubMedPubMedCentral

56.

Alotaibi M. Drug-induced reaction with eosinophilia and systemic symptoms: a review. Cureus. 2023;15(3):e35701. https://doi.org/10.7759/cureus.35701.CrossRefPubMedPubMedCentral

57.

Martinez-Cabriales SA, Rodriguez-Bolanos F, Shear NH. Drug reaction with eosinophilia and systemic symptoms (DReSS): how far have we come? Am J Clin Dermatol. 2019;20(2):217–36. https://doi.org/10.1007/s40257-018-00416-4.CrossRefPubMed

58.

Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: part II. Management and therapeutics. J Am Acad Dermatol. 2013;68(5):709 e1–9; quiz 18–20. https://doi.org/10.1016/j.jaad.2013.01.032.

59.

Gschwend A, Helbling A, Feldmeyer L, Mani-Weber U, Meincke C, Heidemeyer K, et al. Treatment with IL5-/IL-5 receptor antagonists in drug reaction with eosinophilia and systemic symptoms (DRESS). Allergo J Int. 2022:1–8. https://doi.org/10.1007/s40629-022-00224-7.

60.

Wei BM, Fox LP, Kaffenberger BH, Korman AM, Micheletti RG, Mostaghimi A, et al. Drug-induced hypersensitivity syndrome / drug reaction with eosinophilia and systemic symptoms. Part II. Diagnosis and Management. J Am Acad Dermatol. 2023. https://doi.org/10.1016/j.jaad.2023.02.073.

61.

Kim D, Kobayashi T, Voisin B, Jo JH, Sakamoto K, Jin SP, et al. Targeted therapy guided by single-cell transcriptomic analysis in drug-induced hypersensitivity syndrome: a case report. Nat Med. 2020;26(2):236–43. https://doi.org/10.1038/s41591-019-0733-7.CrossRefPubMedPubMedCentral

62.

Walker S, Wang C, Walradt T, Hong BS, Tanner JR, Levinsohn JL, et al. Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome. Blood. 2016;127(7):948–51. https://doi.org/10.1182/blood-2015-06-654277.

63.

King B, Lee AI, Choi J. Treatment of hypereosinophilic syndrome with cutaneous involvement with the JAK inhibitors tofacitinib and ruxolitinib. J Invest Dermatol. 2017;137(4):951–4. https://doi.org/10.1016/j.jid.2016.10.044.CrossRefPubMed

64.

Said JT, Elman SA, Tawa M, Fisher DC, Merola JF, Kupper TS. Topical tofacitinib for the management of lymphocytic-variant hypereosinophilic syndrome with cutaneous involvement. Dermatol Ther. 2022;35(7):e15518. https://doi.org/10.1111/dth.15518.CrossRefPubMed

65.

Stenova E, Tarabcakova L, Babal P, Kasperova S. Hypereosinophilic syndrome-a rare adverse event of anti-cytokine treatment in rheumatoid arthritis resolved after Janus kinase inhibitor therapy. Clin Rheumatol. 2020;39(11):3507–10. https://doi.org/10.1007/s10067-020-05134-z.CrossRefPubMed

66.

Noe MH, Micheletti RG. Systemic interventions for treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis: summary of a Cochrane Review. JAMA Dermatol. 2022;158(12):1436–7. https://doi.org/10.1001/jamadermatol.2022.4543.CrossRefPubMed

67.

Stern RS, Divito SJ. Stevens-Johnson syndrome and toxic epidermal necrolysis: associations, outcomes, and pathobiology-thirty years of progress but still much to be done. J Invest Dermatol. 2017;137(5):1004–8. https://doi.org/10.1016/j.jid.2017.01.003.CrossRefPubMedPubMedCentral

68.

Patel A, Patel A, Solanki D, Mansuri U, Singh A, Sharma P, et al. Hidradenitis suppurativa in the United States: insights from the National Inpatient Sample (2008–2017) on contemporary trends in demographics, hospitalization rates, chronic comorbid conditions, and mortality. Cureus. 2022;14(5):e24755. https://doi.org/10.7759/cureus.24755.CrossRefPubMedPubMedCentral

69.

Kelly G, Sweeney CM, Tobin AM, Kirby B. Hidradenitis suppurativa: the role of immune dysregulation. Int J Dermatol. 2014;53(10):1186–96. https://doi.org/10.1111/ijd.12550.CrossRefPubMed

70.

Prens E, Deckers I. Pathophysiology of hidradenitis suppurativa: an update. J Am Acad Dermatol. 2015;73(5 Suppl 1):S8–11. https://doi.org/10.1016/j.jaad.2015.07.045.CrossRefPubMed

71.

Savage KT, Santillan MR, Flood KS, Charrow A, Porter ML, Kimball AB. Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients. JAAD Case Rep. 2020;6(2):99–102. https://doi.org/10.1016/j.jdcr.2019.10.010.CrossRefPubMedPubMedCentral

72.

Kozera E, Flora A, Frew JW. Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: a retrospective cohort study. J Am Acad Dermatol. 2022;87(6):1440–2. https://doi.org/10.1016/j.jaad.2022.07.047.CrossRefPubMed

73.

Alavi A, Hamzavi I, Brown K, Santos LL, Zhu Z, Liu H, et al. Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies. Br J Dermatol. 2022;186(5):803–13. https://doi.org/10.1111/bjd.20969.CrossRefPubMedPubMedCentral

74.

Sibbald C, Alhusayen R. Janus kinase inhibitors for hidradenitis suppurativa: expanding the therapeutic toolbox. Br J Dermatol. 2022;186(5):768–9. https://doi.org/10.1111/bjd.21297.CrossRefPubMed

75.

Shavit E, Alavi A, Sibbald RG. Pyoderma gangrenosum: a critical appraisal. Adv Skin Wound Care. 2017;30(12):534–42. https://doi.org/10.1097/01.ASW.0000526605.34372.9e.CrossRefPubMed

76.

Sadeghi S, Goodarzi A. Various application of tofacitinib and ruxolitinib (Janus kinase inhibitors) in dermatology and rheumatology: a review of current evidence and future perspective. Dermatol Pract Concept. 2022;12(4):e2022178. https://doi.org/10.5826/dpc.1204a178.CrossRefPubMedPubMedCentral

77.

Sitaru S, Biedermann T, Lauffer F. Successful treatment of pyoderma gangrenosum with Janus kinase 1/2 inhibition. Open Access Journal of the European Academy of Dermatology & Venereology. 2022;1(4):420–3. https://doi.org/10.1002/jvc2.62.CrossRef

78.

Scheinberg M, Machado LA, LG MC, Ferreira SB, Michalany N. Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor. J Transl Autoimmun. 2021;4:100099. https://doi.org/10.1016/j.jtauto.2021.100099.

79.

Kochar B, Herfarth N, Mamie C, Navarini AA, Scharl M, Herfarth HH. Tofacitinib for the treatment of pyoderma gangrenosum. Clin Gastroenterol Hepatol. 2019;17(5):991–3. https://doi.org/10.1016/j.cgh.2018.10.047.CrossRefPubMed

80.

La Rocca G, Ferro F, Baldini C, Libra A, Sambataro D, Colaci M, et al. Targeting intracellular pathways in idiopathic inflammatory myopathies: a narrative review. Front Med (Lausanne). 2023;10:1158768. https://doi.org/10.3389/fmed.2023.1158768.CrossRefPubMed

81.

Paudyal A, Zheng M, Lyu L, Thapa C, Gong S, Yang Y, et al. JAK-inhibitors for dermatomyositis: a concise literature review. Dermatol Ther. 2021;34(3):e14939. https://doi.org/10.1111/dth.14939.CrossRefPubMed

82.

Paik JJ, Lubin G, Gromatzky A, Mudd PN Jr, Ponda MP, Christopher-Stine L. Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review. Clin Exp Rheumatol. 2023;41(2):348–58. https://doi.org/10.55563/clinexprheumatol/hxin6o.CrossRefPubMed

83.

Mastrolia MV, Orsini SI, Marrani E, Maccora I, Pagnini I, Simonini G. Efficacy of Janus kinase inhibitor baricitinib in the treatment of refractory juvenile dermatomyositis complicated by calcinosis. Clin Exp Rheumatol. 2023;41(2):402–3. https://doi.org/10.55563/clinexprheumatol/7k9ajj.CrossRefPubMed

84.

Ding Y, Huang B, Wang Y, Hou J, Chi Y, Zhou Z, et al. Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis. Ann Rheum Dis. 2021;80(4):543–5. https://doi.org/10.1136/annrheumdis-2020-218582.CrossRefPubMed

85.

Hornung T, Janzen V, Heidgen FJ, Wolf D, Bieber T, Wenzel J. Remission of recalcitrant dermatomyositis treated with ruxolitinib. N Engl J Med. 2014;371(26):2537–8. https://doi.org/10.1056/NEJMc1412997.CrossRefPubMed

86.

Talty R, Damsky W, King B. Treatment of cutaneous sarcoidosis with tofacitinib: a case report and review of evidence for Janus kinase inhibition in sarcoidosis. JAAD Case Rep. 2021;16:62–4. https://doi.org/10.1016/j.jdcr.2021.08.012.CrossRefPubMedPubMedCentral

87.

Damsky W, Thakral D, McGeary MK, Leventhal J, Galan A, King B. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. J Am Acad Dermatol. 2020;82(3):612–21. https://doi.org/10.1016/j.jaad.2019.05.098.CrossRefPubMed

88.

Wei JJ, Kallenbach LR, Kreider M, Leung TH, Rosenbach M. Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera. JAAD Case Rep. 2019;5(4):360–1. https://doi.org/10.1016/j.jdcr.2019.02.006.CrossRefPubMedPubMedCentral

89.

Singh K, Wang A, Heald P, McNiff JM, Suozzi K, King B, et al. Treatment of angiolupoid sarcoidosis with tofacitinib ointment 2% and pulsed dye laser therapy. JAAD Case Rep. 2021;7:122–4. https://doi.org/10.1016/j.jdcr.2020.11.016.CrossRefPubMed

90.

Alam M, Fang V, Rosenbach M. Treatment of cutaneous sarcoidosis with tofacitinib 2% ointment and extra virgin olive oil. JAAD Case Rep. 2021;9:1–3. https://doi.org/10.1016/j.jdcr.2020.12.021.CrossRefPubMed

Title: JAK Inhibitor Use for the Inpatient Dermatologist
Authors: Eric Xia
Ahana Gaurav
Allison Yan
Arash Mostaghimi
Publication date: 18-11-2023
Publisher: Springer US
Keywords: Atopic Dermatitis
Acne Inversa
Vulgar Psoriasis
Dermatomyositis
Pyoderma Gangrenosum
Graft-Versus-Host Disease
Graft-Versus-Host Disease
Published in: Current Dermatology Reports / Issue 4/2023
Electronic ISSN: 2162-4933
DOI: https://doi.org/10.1007/s13671-023-00412-w

Keynote webinar | Spotlight on medication adherence

Springer Medicine

JAK Inhibitor Use for the Inpatient Dermatologist

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2023

Teledermatology Lessons During the COVID-19 Pandemic

Incontinence-Associated Dermatitis: a Practical Guide for the Consulting Dermatologist

Minimal Eliciting Allergic Contact Dermatitis Concentrations in Normal versus Damaged Skin: Clinical and Toxicologic Relevance

Allergic Contact Dermatitis in Older Adults

Immune Checkpoint Inhibitors and Systemic Side Effects: Overview for the Inpatient Dermatologist

The Safety and Accuracy of Drug Patch Testing in Delayed Hypersensitivity Reactions